Brief: Obseva Provides Update On Yselty (Linzagolix) Clinical Development Program

Obseva SA

11/01/2021 06:05

Jan 11 (Reuters) - Obseva SA  OBSN.S :
    * OBSEVA PROVIDES UPDATE ON YSELTY® (LINZAGOLIX) CLINICAL
DEVELOPMENT PROGRAM
    * EUROPEAN MEDICINES AGENCY VALIDATES YSELTY MAA FOR UTERINE
FIBROIDS; US NDA PLANNED FOR 1H 2021
    * PHASE 3 EDELWEISS 3 (CONDUCTED IN EUROPE AND US) STUDY OF
YSELTY
FOR TREATMENT OF ENDOMETRIOSIS IS PROGRESSING AS PLANNED;
PRIMARY ENDPOINT READOUT EXPECTED 4Q 2021
    * PHASE 3 EDELWEISS 2 (CONDUCTED IN UNITED STATES) YSELTY
ENDOMETRIOSIS STUDY DISCONTINUED DUE TO ENROLLMENT CHALLENGES;
NO SAFETY CONCERNS IDENTIFIED

Source text for Eikon:  ID:nGNEbCwBpB 
Further company coverage:  OBSN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))